Health
Commented by Nico Popp on March 17th, 2021 | 07:25 CET
Fresenius SE, Q+M Dental Group, Siemens Healthineers: Where growth meets dividends
The back-and-forth surrounding AstraZeneca's vaccine has unsettled many people. But the discussion about extremely rare side effects also shows: Vaccines and drugs are subject to strict regulations and the healthcare system is strictly regulated. While pharmaceutical companies must always expect setbacks, especially in accelerated approval procedures, the situation is different for suppliers of medical technology or consumables. We present three stocks that are benefiting from rising healthcare spending.
Read
Commented by Stefan Feulner on February 9th, 2021 | 08:00 CET
CureVac, Cardiol Therapeutics, Bayer - roaring profits!
The race for the best and most effective vaccine is in full swing. After BioNTech and its partner Pfizer, Moderna and AstraZeneca were approved in Europe, but there are always obstacles. Over the weekend, for example, South Africa announced that it is forgoing the AstraZeneca vaccine for the time being. The background to this is its supposedly lower efficacy with the B.1.351 virus mutation. Somewhat unnoticed, another vaccine manufacturer is moving into pole position through innovative collaborations.
Read
Commented by Nico Popp on February 8th, 2021 | 07:30 CET
Fresenius, Fresenius Medical Care, Q&M Dental: Healthy returns await here
Healthcare stocks have been in demand not just since the pandemic, but the pandemic is a sure game-changer for the industry in the long term. Demand for consumables and tests will continue to rise because this much seems certain: the Coronavirus will remain with us and possibly return year after year like a wave of influenza. Companies in the industry can profit from this. We present three stocks.
Read
Commented by André Will-Laudien on January 28th, 2021 | 10:39 CET
Fresenius - Q&M Dental Group - IBU-tec: New price explosions every day!
Rarely has the stock market been so volatile and exciting as in the last few days. Hedge fund Melvin Capital had to close out because of the GameStop share, and now the next wave is probably looming with AMC Entertainment. A full 270% went through the roof right at the opening; according to the New York Stock Exchange (NYSE) thousands of buy orders were already there at opening. Again, there had been a recommendation in a social media channel. On the Nasdaq, it jumped rapidly from USD 5 to USD 21 right at the opening - something you rarely see. And GameStop continues today after yesterday's debacle! After several trading suspensions, the value exploded further from USD 149 to USD 380 after a good hour of trading. That should have been the end of trading school for many new entrants!
Read
Commented by Nico Popp on January 19th, 2021 | 10:50 CET
Pfizer, Q&M Dental Group, Johnson & Johnson: Where do profiteers of the pandemic lurk?
We all know that one's health is the most important thing. But from time to time, this truism slips out of focus. The pandemic has shown that neither fame nor money can protect you from getting sick. A big step toward being healthy, however, can be made by trusting in research. The development of vaccines in record time has shown how great the potential is in science and the pharmaceutical industry. New test methods are continually coming onto the market. Three shares show that there is money to be made on the stock market from these developments.
Read
Commented by Carsten Mainitz on January 12th, 2021 | 10:28 CET
CureVac, Q&M Dental, Moderna - What you didn't know - really exciting!
The World Health Organization (WHO) recorded more than 235 Covid-19 vaccine projects worldwide since January 2020, but few projects make it across the finish line. Timing is a critical factor, and early entrants will divide the huge market among themselves. These include BioNTech/Pfizer, Moderna and AstraZeneca. Still in the "test phase" is Tübingen-based CureVac, which recently entered into a sales cooperation with Bayer. Information published yesterday is positive and suggests approval of the preparation by the beginning of the second quarter of 2021 at the latest. Away from vaccine manufacturers, other Corona profiteers exist with which investors can earn handsomely. Q&M Dental from Singapore is little known. Its subsidiary is one of nine government-approved Corona testing facilities. Also, Q&M supplies Asian neighboring countries with millions of its Corona testing. We inform you about the news and potentials of known and unknown players.
Read
Commented by André Will-Laudien on December 23rd, 2020 | 08:50 CET
Q & M Dental, Moderna, AstraZeneca: Serving people!
Rarely has the stock market been so focused on people as it has been during the pandemic. People are thinking about which companies offer the best service package for all the problems associated with infections, vaccinations and even the psychological effects of isolation and loneliness. Humans are "social animals" with multiple social needs. Curtailing these needs works temporarily, but at some point, the arguments have to be genuinely purposeful so that certain restrictions continue to be accepted. At the peak of the contagion curve, we would like to see possible remedies that quickly turn the overall situation into a positive end - this is possible for the medium-term future. Still, in the short term, we have to stick together.
Read
Commented by André Will-Laudien on October 27th, 2020 | 10:17 CET
Pfizer, GlaxoSmithKline, EXMceuticals - Research in competition
By the end of 2020, the drug market is expected to more than double to USD 1.3 trillion, with the E7 countries - Brazil, China, India, Indonesia, Mexico, Russia and Turkey - accounting for about one-fifth of global drug sales. Also, the incidence of chronic diseases in developing countries will increasingly resemble that in industrialized countries. The evidence is abundant that the pharmaceutical industry business model is both economically unsustainable and operationally lethargic to produce the types of innovative treatments demanded by global markets. The industry must fundamentally change the way it operates to take full advantage of future growth opportunities. PwC's management consultants expect the industry to shift its focus from treatment to prevention. The traditional blockbuster sales model will disappear, and sophisticated direct sales channels will diminish the role of wholesalers. Let's take a closer look!
Read
Commented by Mario Hose on September 29th, 2020 | 10:51 CEST
BioNTech, Bayer, Valeo Pharma: Share price jump ahead of quarterly results
Investors' expectations of developments can drive the share price. When it comes to solving a problem or creating needs, the interest of the capital market is particularly high. Things get exciting for investors when the business model offers the possibilities of scalability. Attractive investment opportunities can be created in the fields of health and medicine, which offer extraordinary return opportunities.
Read
Commented by Mario Hose on July 29th, 2020 | 07:29 CEST
BioNTech, Eastman Kodak, EXMceuticals - investors have the chance to profit
The importance of health has not been as clear for a long time as it was in 2020. Detached from the discussion about the specifics of COVID-19 on mortality compared to other viruses, the need for protection is great and helplessness without a medical response is harmful to the common good. For this reason, experts around the globe are working to find active ingredients and reduce dependence on China for care. Investors have the opportunity to profit from this development.
Read